⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for real world evidence

Every month we try and update this database with for real world evidence cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line TreatmentNCT06311383
Breast Cancer
First-line Ribo...
First-line endo...
First-line chem...
18 Years - Novartis
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in FinlandNCT05701007
Metastatic Cast...
Metastatic Cast...
abiraterone
enzalutamide
docetaxel
apalutamide
cabazitaxel
Radium-223
Lutetium-177
degarelix
goserelin
leuprorelin
triptorelin
18 Years - Pfizer
Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)NCT04031898
Lung Cancer
Non Interventio...
- AstraZeneca
First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese SettingNCT04391283
Carcinoma, Non-...
Osimertinib
18 Years - First Affiliated Hospital of Zhejiang University
PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTcNCT04814095
Cancer
QOL
CT imaging
18 Years - British Columbia Cancer Agency
Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)NCT04031898
Lung Cancer
Non Interventio...
- AstraZeneca
RWD Study in HER2+ mBC Patients in Third-Line TherapyNCT04566458
Breast Cancer S...
No intervention
18 Years - Exactis Innovation
First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese SettingNCT04391283
Carcinoma, Non-...
Osimertinib
18 Years - First Affiliated Hospital of Zhejiang University
Tenosynovial Giant Cell Tumors (TGCT) Observational Platform ProjectNCT02948088
Giant Cell Tumo...
18 Years - Daiichi Sankyo
RWD Study in HER2+ mBC Patients in Third-Line TherapyNCT04566458
Breast Cancer S...
No intervention
18 Years - Exactis Innovation
A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United KingdomNCT04936399
Esophageal Squa...
Nivolumab
18 Years - Bristol-Myers Squibb
PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTcNCT04814095
Cancer
QOL
CT imaging
18 Years - British Columbia Cancer Agency
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: